Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

This study introduced the C-CAT, a new assessment tool for central centrifugal cicatricial alopecia, and found that established treatments improved symptoms in most patients over six months.

In this randomized controlled trial, the nutritional supplement PPT5 α was associated with increased terminal hair percentages and improved self-assessed hair parameters in women with early-stage androgenetic alopecia.

In this study, PTH-CBD effectively prevented and partially reversed chemotherapy-induced alopecia in mice, with pretreatment offering a better cosmetic outcome compared to therapeutic administration after hair loss onset.

This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This report describes a 60-year-old female with pretibial pruritic papular dermatitis who showed significant improvement of skin lesions after one month of treatment with oral pentoxifylline. The authors highlight the unique clinical and histological features of PPPD and propose pentoxifylline as a potential therapy.

This article reviews the potential applications of Point of Care procedures in radiology, discussing their ability to enhance the speed of diagnosis and treatment but does not report new results.

This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.

The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.

This study found that combining a thulium laser with intra-perifollicular PDRN injections significantly improved hair thickness but not hair counts compared to mesotherapy and PDRN in patients with pattern hair loss.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.

This study found that topical patidegib gel significantly shrank basal cell carcinomas in Gorlin syndrome patients without causing the systemic side effects common with oral hedgehog inhibitors.

This study found that prolonged acute tissue expansion notably increased the amount of scalp tissue removed during scalp reduction surgery in three patients.

This study found that regenerating the Pd/C finasteride synthesis catalyst using methanol extraction and nitric acid oxidation achieved a pregnendone conversion of 97.5%.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.

This study found that loss of Ptch1 function in mouse skin's basal cells is sufficient to rapidly induce tumors resembling human basal cell carcinoma, suggesting Ptch1 as a key tumor suppressor.

This study found no significant difference in SARS-CoV2 IgG seroconversion rates between patients with immune-mediated inflammatory diseases treated with targeted immune-modulating therapies and those on conventional systemic treatments.

CTP-543 is generally safe for treating alopecia areata.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

Scalp cooling significantly reduces hair loss in chemotherapy patients.

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.

This study demonstrated that transcutaneous vaccination via cyanoacrylate skin surface stripping effectively induced both CD4 and CD8 T cell responses in humans, offering a promising alternative to intramuscular injection.

This study found that both crude Spirulina extract and C-phycocyanin showed similar effects on keratinocyte proliferation and wound healing, with C-phycocyanin performing better in tissue regeneration in vivo on the 7th day.

In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.